WebBNTX Stock Summary. BNTX's current price/earnings ratio is 3.02, which is higher than merely 4.86% of US stocks with positive earnings. With a year-over-year growth in debt of -35.15%, BIONTECH SE's debt growth rate surpasses merely 8.03% of about US stocks. WebMar 27, 2024 · The outlook comes on the heels of a strong fourth-quarter report. BioNTech earned 9.26 euros a share on 4.28 billion euros in sales. That comes out to about $9.97 …
Baldwin Brothers LLC MA Buys 164 Shares of BioNTech SE (NASDAQ:BNTX)
WebApr 9, 2024 · BioNTech Stock Up 2.6 %. Shares of NASDAQ BNTX opened at $128.90 on Friday. The company has a current ratio of 7.43, a quick ratio of 7.28 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12-month low of $117.08 and a 12-month high of $188.99. The firm’s 50-day moving average price is $133.36 and its 200-day moving average price … WebApr 8, 2024 · Systrade AG bought a new stake in BioNTech SE (NASDAQ:BNTX - Get Rating) during the fourth quarter, according to its most recent disclosure with the SEC.The firm bought 10,000 shares of the company's stock, valued at approximately $1,502,000. BioNTech comprises about 1.3% of Systrade AG's holdings, making the stock its 6th … dahimu corp chicago il
JP Morgan Maintains BioNTech SE (BNTX) Neutral Recommendation
WebApr 7, 2024 · Fintel reports that on April 10, 2024, JP Morgan maintained coverage of BioNTech SE (NASDAQ:BNTX) with a Neutral recommendation. As of April 7, 2024, the … WebApr 5, 2024 · BNTX / Overview BioNTech SE ADR U.S.: Nasdaq Add to Watchlist 0.00 BNTX Real Time Quote About BioNTech SE ADR BioNTech SE engages in the development of novel medicines at the intersection... WebFounded. 2008. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, … dahisar college